AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06387069
Drug: Salvage Chemotherapy Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:~* MEC regimen: etoposide injection 100 mg/m2, cytarabine injection 1000 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).~* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4).~* LoDAC: cytarabine injection 20 mg q12h SC or IV for 10 consecutive days (Days 1-10).~* Azacitidine: azacitidine injection 75 mg/m2 QD SC or IV for 7 consecutive days (Days 1-7).
Trial: NCT05434494
Drug: remifantanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
Trial: NCT04728646
Drug: DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
Trial: NCT04884763
Drug: Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
Trial: NCT05934110
Drug: EMP16-120/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID).
Trial: NCT05934110
Drug: EMP16-60/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)
Trial: NCT05934110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)
Trial: NCT04762836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control in oral form
Trial: NCT04884880
Drug: Luo-Fu-Shan Plaster
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luo-Fu-Shan Plaster 10g，once daily，4 weeks
Trial: NCT04884880
Drug: The placebo 10g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10g，once daily，4 weeks
Trial: NCT05322330
Drug: Flu
RxNorm normalized name: Fluex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-30 mg/m2，d-5 ～d-3，qd，ivgtt
Trial: NCT05322330
Drug: CTX
RxNorm normalized name: CTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250-500 mg/m2，d-5 ～d-3，qd，ivgtt
Trial: NCT05750355
Drug: TPN171H 10 mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
Trial: NCT05750355
Drug: TPN171H 30 mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
Trial: NCT05750355
Drug: TPN171H 40 mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
Trial: NCT05750355
Drug: TPN171H 50 mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
Trial: NCT04886986
Drug: 177Lu-PSMA-I&T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.
Trial: NCT06133192
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroids 2 mg/kg/d
Trial: NCT05061979
Drug: BAY1747846
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous (IV) injection, single dose
Trial: NCT04798222
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.
Trial: NCT04798222
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
Trial: NCT06171776
Drug: RetroMTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium silicate lining material work as dentin substitute
Trial: NCT06171776
Drug: TheraCal
RxNorm normalized name: TheraCal D2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium silicat material light cured
Trial: NCT04798222
Drug: Treatment G
RxNorm normalized name: VanaLice Lice Killing Treatment Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.
Trial: NCT04798222
Drug: Treatment H
RxNorm normalized name: Walgreens Lice Treatment Homeopathic Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral dose of dapagliflozin capsule in fasted condition.
Trial: NCT04859751
Drug: VB4-845 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical administration of VB4-845 Injection.
Trial: NCT06090955
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
Trial: NCT05626179
Drug: [14C] IBI351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral formulation of \[14C\] IBI351 was formulated as a suspension for subjects to take orally in drinking water under fasting conditions
Trial: NCT04798209
Drug: Placebo (SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-777991 matching placebo administered as hard capsules for oral use.
Trial: NCT04798209
Drug: Placebo (MAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered as hard capsules for oral use, once daily.
Trial: NCT05600361
Drug: hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
Trial: NCT04972188
Drug: ZYIL1 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLRP3 inflammasome inhibitor
Trial: NCT04798209
Drug: Microtracer matching placebo (SAD - Absolute Bioavailability)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
Trial: NCT05246878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match EDP-235, oral administration
Trial: NCT05895123
Drug: Rosuvastatin 20 mg
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive one tablet rosuvastatin 20 mg every night
Trial: NCT04798209
Drug: Microtracer matching placebo (MAD - ADME)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
Trial: NCT04734860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent solution
Trial: NCT05468645
Drug: [14C]Hemay005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
Trial: NCT06469190
Drug: KN5501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy.
Trial: NCT06632990
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine, oral, 100mg administered before study drug and after study drug
Trial: NCT06632613
Drug: ENN0403 capsules, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules will be orally administered once a day for 5 consecutive days at low dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
Trial: NCT06632613
Drug: ENN0403 capsules, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules will be orally administered once a day for 5 consecutive days at high dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the placebo capsules will be administrated through a nasogastric tube/oral gastric tube.
Trial: NCT06184685
Drug: Diclofenac Microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
Trial: NCT05891483
Drug: SHR-1905 Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1905 Placebo Injection
Trial: NCT06071442
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oral coated tablets of Rosuvastatin.
Trial: NCT06071442
Drug: Levonorgestrel / Ethinyl Estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol.
Trial: NCT05230511
Drug: Lactobacillus RhamnosusGG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
Trial: NCT05814718
Drug: modified BEAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
Trial: NCT06069830
Drug: 4 cycles of ESA regimen with sandwiched radiotherapy
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
Trial: NCT03851627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Arm
Trial: NCT05706207
Drug: HB0030 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Trial: NCT05706207
Drug: HB0030 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Trial: NCT05706207
Drug: HB0030 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Trial: NCT05706207
Drug: HB0030 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Trial: NCT05706207
Drug: HB0030 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Trial: NCT05706207
Drug: HB0030 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Trial: NCT05706207
Drug: HB0030 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Trial: NCT05706207
Drug: HB0030 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Trial: NCT05324592
Drug: 9MW0813
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously.
Trial: NCT05519111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo equivalent
Trial: NCT06005558
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.
Trial: NCT05551793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: SC injections of equivalent volume
Trial: NCT04982705
Drug: [Part 1.1] IDG-16177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Part 1.1\] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
Trial: NCT04982705
Drug: [Part 1.1] Placebo of IDG-16177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Part 1.1\] subjects will receive a single oral dose of IMP.
Trial: NCT04982705
Drug: [Part1.2] IDG-16177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Part 1.2\] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
Trial: NCT04982705
Drug: [Part 2] IDG-16177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Part 2\] Administration once daily for 4 weeks.
Trial: NCT04982705
Drug: [Part 1.2] Placebo of IDG-16177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Part 1.2\] Administration once daily for 14 days.
Trial: NCT04982705
Drug: [Part 2] Placebo of IDG-16177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Part 2\] Administration once daily for 4 weeks.
Trial: NCT05340530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a placebo.
Trial: NCT04514731
Drug: Isotonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.
Trial: NCT04524221
Drug: PTG-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTG-100, 600mg taken twice daily in capsule form for 42 days
Trial: NCT04524221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken twice daily in capsule form for 42 days
Trial: NCT04893512
Drug: Orally Suspension of CoV2-OGEN1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
Trial: NCT06554561
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 4-6 cycles will be prescribed.
Trial: NCT05093296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)
Trial: NCT05921591
Drug: IRL201104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilised powder for reconstitution for IV dosing
Trial: NCT05921591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for IRL201104
Trial: NCT06110429
Drug: Lactate, Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isovolemic and osmotic infusion Comparison of osmotic agent
Trial: NCT05985798
Drug: Sin-Bev-TACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.
Trial: NCT06110429
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isovolemic and osmotic infusion Comparison of osmotic agent
Trial: NCT05498181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05976568
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
Trial: NCT06381661
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50mg (in children: 1-2 mg/kg) IV Q6 for 7 days
Trial: NCT06381661
Drug: Hydrocortisone and fludrocortisone
RxNorm normalized name: fludrocortisone and antiinfectives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 50mg IV Q6 for 7 days + Fludrocortisone 50mg orally or via gastric tube once a day for 7 days.
Trial: NCT06381661
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic unfractionated heparin (UFH) starting at 400 (in children: 20 IU/kg/h) IU/kg/24h (target between 0.3 and 0.5 IU/ml), adapted to the therapeutic Partial Thromboplastin Time targeting values in the range of 60 to 100 seconds, with lower intensity dosing in the range of 60 to 80 seconds, for 7 days (or ICU discharge, pending which will occur first).
Trial: NCT06381661
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in children 100 U/kg) IU/kg/24h, for 7 days (or hospital discharge pending which will occur first).
Trial: NCT06381661
Drug: Recombinant humanThrombomodulin( rhTM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human thrombomodulin (rhTM) 0.06 mg/kg/j IV, for 7 days (or ICU discharge, pending which will occur first).
Trial: NCT04545424
Drug: Neuromuscular Blocking Agents
RxNorm normalized name: NEUROMUSCULAR BLOCKING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
Trial: NCT05842746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
Trial: NCT05490316
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05937386
Drug: AGMB-129
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT04887194
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BCRP probe substrate
Trial: NCT06293716
Drug: CVL237 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
Trial: NCT06293716
Drug: CVL237 placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
Trial: NCT06718309
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin. The chemotherapy treatment lasts 3 cycles.
Trial: NCT06718309
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators choose PD-1 or PD-L1 according to drug indication and the immunotherapy lasts 3 cycles preoperatively and 1 year after surgery.
Trial: NCT06718998
Drug: NNC0519-0130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.